Compare Moody's Corporation (MCO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Neurocrine Biosciences Inc — how do they compare? Moody's Corporation trades at $476.73 (market cap $82.80B), while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: Moody's Corporation is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MCO | NBIX | |
|---|---|---|
Market Cap | $82.80B | $16.76B |
Sector | Financials | Health |
52-Week High | $539.61 | $185.50 |
52-Week Low | $412.23 | $123.10 |
Enterprise Value | $88.83B | $16.78B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $477.75, up 0.98% on the day, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $4.68 versus $4.26 expected, driven by robust debt issuance and analytics demand. Revenue growth accelerated to 15% year-over-year, with net income margin expanding to 34.25%. The stock is supported by a consensus price target of $561.88, indicating 17.6% upside potential, and positive analyst sentiment with 56% buy ratings.
Outlook remains positive due to consistent earnings beats, high profitability, and strategic positioning in credit ratings. Risks include elevated valuation multiples, such as a P/E of 30.31, and dependence on capital market activity. Investors should weigh growth prospects against potential macroeconomic headwinds affecting debt issuance volumes.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
